Glioblastoma targeted therapy: updated approaches from recent biological insights
Reads0
Chats0
TLDR
The most promising biological insights that have opened the way for the development of targeted therapies in glioblastoma are reviewed, and recent data from clinical trials evaluating targeted therapies and immunotherapies are examined.About:
This article is published in Annals of Oncology.The article was published on 2017-07-01 and is currently open access. It has received 304 citations till now. The article focuses on the topics: Targeted therapy & Precision medicine.read more
Citations
More filters
The somatic genomic landscape of glioblastoma
Cameron Brennan,Roel G.W. Verhaak,Aaron McKenna,Benito Campos,Houtan Noushmehr,Sofie R. Salama,Siyuan Zheng,Debyani Chakravarty,J. Zachary Sanborn,Samuel H. Berman,Rameen Beroukhim,Brady Bernard,Chang-Jiun Wu,Giannicola Genovese,Ilya Shmulevich,Jill S. Barnholtz-Sloan,Lihua Zou,Rahulsimham Vegesna,Sachet A. Shukla,Giovanni Ciriello,W. K. Yung,Wei Zhang,Carrie Sougnez,Tom Mikkelsen,Kenneth Aldape,Darell D. Bigner,Erwin G. Van Meir,Michael D. Prados,Andrew E. Sloan,Keith L. Black,Jennifer M. Eschbacher,Gaetano Finocchiaro,William A. Friedman,David W. Andrews,Abhijit Guha,Mary Iacocca,Brian P. O'Neil,Greg Foltz,Jerome Myers,Daniel J. Weisenberger,Robert Penny,Raju Kucherlapati,Charles M. Perou,D. Neil Hayes,Richard A. Gibbs,Marco A. Marra,Gordon B. Mills,Eric S. Lander,Paul T. Spellman,Richard K. Wilson,Chris Sander,John N. Weinstein,Matthew Meyerson,Stacey Gabriel,Peter W. Laird,David Haussler,Gad Getz,Lynda Chin +57 more
TL;DR: In this article, the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs) was described, including several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA.
Journal ArticleDOI
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia,Herbert Hurwitz,Alan Sandler,David Miles,Robert L. Coleman,Regula Deurloo,Olivier Chinot +6 more
TL;DR: Overall, bevacizumab is expected to remain a key agent in cancer therapy, both due to its established efficacy in approved indications and its promise as a partner in novel targeted combination treatments.
Journal ArticleDOI
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi,Gian Luca De Salvo,Alba A. Brandes,Marica Eoli,Roberta Rudà,Marina Faedi,Ivan Lolli,Andrea Pace,Bruno Daniele,Francesco Pasqualetti,Simona Rizzato,Luisa Bellu,Ardi Pambuku,Miriam Farina,Giovanna Magni,Stefano Indraccolo,Marina Paola Gardiman,Riccardo Soffietti,Vittorina Zagonel +18 more
TL;DR: Overall survival was significantly improved in the regorafenib group compared with the lomustine group, with a median overall survival of 7·4 months, and an encouraging overall survival benefit of regorAFenib in recurrent glioblastoma.
Journal ArticleDOI
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley,Thomas Kaley,Mehdi Touat,Vivek Subbiah,Antoine Hollebecque,Jordi Rodon,A. Craig Lockhart,Vicki L. Keedy,Franck Bielle,Ralf Hofheinz,Florence Joly,Jean-Yves Blay,Ian Chau,Igor Puzanov,Noopur Raje,Jürgen Wolf,Lisa M. DeAngelis,Lisa M. DeAngelis,Martina Makrutzki,Todd Riehl,Bethany Pitcher,José Baselga,José Baselga,David M. Hyman,David M. Hyman +24 more
TL;DR: Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype.
Journal ArticleDOI
Embryonic Stem Cells-Derived Exosomes Endowed with Targeting Properties as Chemotherapeutics Delivery Vehicles for Glioblastoma Therapy.
Qingwei Zhu,Xiaozheng Ling,Yunlong Yang,Juntao Zhang,Qing Li,Xin Niu,Guowen Hu,Bi Chen,Haiyan Li,Yang Wang,Zhifeng Deng +10 more
TL;DR: Results show that cRGD‐Exo‐PTX significantly improves the curative effects of PTX in GBM via enhanced targeting, indicating that ESC‐exos are potentially powerful therapeutic carriers for GBM and could have utility in many other diseases.
References
More filters
Journal ArticleDOI
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q. Lee,Vinay K. Puduvalli,Joel M. Reid,John G. Kuhn,Kathleen R. Lamborn,Timothy F. Cloughesy,Susan M. Chang,Jan Drappatz,Jan Drappatz,W. K. Alfred Yung,Mark R. Gilbert,H. Ian Robins,Frank S. Lieberman,Andrew B. Lassman,Renee M. McGovern,Jihong Xu,Serena Desideri,Xiabu Ye,Matthew M. Ames,Igor Espinoza-Delgado,Michael D. Prados,Patrick Y. Wen +21 more
TL;DR: Vorinostat in combination with temozolomide is well tolerated in patients with high-grade glioma and a phase I/II trial of vor inostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.
Journal ArticleDOI
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
S. Lv,Erik Teugels,Jan Sadones,Sylvia De Brakeleer,Johnny Duerinck,Stephanie Du Four,Alex Michotte,Jacques De Greve,Bart Neyns +8 more
TL;DR: Observations indicate that the type of EGFR mutation may determine the outcome of GB patients treated with the EGFR-targeted monoclonal antibody cetuximab in a prospective phase II clinical trial, and Prospective investigation of both the EG FR amplification status and mutation status in clinical trials with EGFR -targeted therapies for GB is indicated.
Journal ArticleDOI
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
Matthias Holdhoff,Jeffrey G. Supko,Gary L. Gallia,Christine L. Hann,David Bonekamp,Xiaobu Ye,Bing Cao,Alessandro Olivi,Stuart A. Grossman +8 more
TL;DR: It is suggested that imatinib can reach intratumoral concentrations similar to those or higher than in plasma in regions of glioblastoma where the BBB is disrupted as indicated by contrast enhancement on magnetic resonance imaging.
Journal ArticleDOI
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Andreas F. Hottinger,A. Ben Aissa,Vittoria Espeli,D. Squiban,N. Dunkel,Maria Vargas,Thomas Hundsberger,Nicolas Mach,Karl Lothard Schaller,Damien C. Weber,A Bodmer,Dietrich Py +11 more
TL;DR: Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas and the robust PK data of the TMZ/Sb combination could be useful in other cancer settings.
Journal ArticleDOI
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
Ranjith Babu,D. Cory Adamson +1 more
TL;DR: Rindopepimut is a peptide vaccine which elicits EGFRvIII-specific humoral and cellular immune responses which results in significantly higher progression-free and overall survival times in vaccinated patients with EGFR vIII-expressing GBM tumors.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G.W. Verhaak,Katherine A. Hoadley,Elizabeth Purdom,Victoria Wang,Yuan-yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd R. Golub,Jill P. Mesirov,Gabriele Alexe,Michael S. Lawrence,Michael O'Kelly,Pablo Tamayo,Barbara A. Weir,Stacey Gabriel,Wendy Winckler,Supriya Gupta,Lakshmi Jakkula,Heidi S. Feiler,J. Graeme Hodgson,C. David James,Jann N. Sarkaria,Cameron Brennan,Ari B. Kahn,Paul T. Spellman,Richard K. Wilson,Terence P. Speed,Terence P. Speed,Joe W. Gray,Matthew Meyerson,Gad Getz,Charles M. Perou,Charles M. Perou,D. Neil Hayes +34 more
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more